4.3 Article

Colorectal cancer tumor stem cells mediate bevacizumab resistance through the signal IL-22-STAT3 signaling pathway

相关参考文献

注意:仅列出部分参考文献,下载原文获取全部文献信息。
Letter Immunology

Musculin is highly enriched in Th17 and IL-22-producing ILC3s and restrains pro-inflammatory cytokines in murine colitis

Jun Yan et al.

Summary: Transcription suppressor Musculin (MSC) is enriched in pro-inflammatory Th17 and IL-22-producing ILC3s. MSC-/- mice show more severe pathology in DSS-induced colitis, but the symptoms can be reversed by IL-22 antagonism. This suggests the existence of an MSC:IL-22 regulatory axis.

EUROPEAN JOURNAL OF IMMUNOLOGY (2021)

Article Multidisciplinary Sciences

Mathematical simulation of tumour angiogenesis: angiopoietin balance is a key factor in vessel growth and regression

Hayato Yanagisawa et al.

Summary: Excessive tumour growth leads to hypoxic environment and tumour angiogenesis. We developed a 3D simulation model incorporating both angiogenesis and tumour growth, and found that using the drug bevacizumab effectively inhibits tumour growth, with better efficacy observed with early administration.

SCIENTIFIC REPORTS (2021)

Article Oncology

Randomized Phase III Trial of Gemcitabine and Cisplatin With Bevacizumab or Placebo in Patients With Advanced Urothelial Carcinoma: Results of CALGB 90601 (Alliance)

Jonathan E. Rosenberg et al.

Summary: The study showed that adding bevacizumab to GC did not improve overall survival in patients with metastatic urothelial carcinoma, despite a slight advantage in progression-free survival. Increased bevacizumab-related toxicities were observed in the bevacizumab-treated group.

JOURNAL OF CLINICAL ONCOLOGY (2021)

Article Cell & Tissue Engineering

DPSCs treated by TGF-β1 regulate angiogenic sprouting of three-dimensionally co-cultured HUVECs and DPSCs through VEGF-Ang-Tie2 signaling

Yuchen Zhang et al.

Summary: This study showed that TGF-beta 1 can induce DPSC differentiation into functional pericyte-like cells. T-DPSCs maintain vessel stability through Ang1/Tie2 and VEGF/VEGFR2 signaling.

STEM CELL RESEARCH & THERAPY (2021)

Article Oncology

Metastatic Colorectal Cancer Patient With Microsatellite Stability and BRAFV600E Mutation Showed a Complete Metabolic Response to PD-1 Blockade and Bevacizumab: A Case Report

Chongkai Fang et al.

Summary: The majority of colorectal cancer patients with microsatellite stability or proficient mismatch repair are refractory to immunotherapeutic strategies. Current research focuses on combined treatment strategies to improve the efficacy of immunotherapy among these patients. Colorectal cancer patients with MSS and the BRAF(V600E) mutation show a worse prognosis and minimal benefit from immunotherapy.

FRONTIERS IN ONCOLOGY (2021)

Review Cell Biology

Human Liver Stem Cells: A Liver-Derived Mesenchymal Stromal Cell-Like Population With Pro-regenerative Properties

Stefania Bruno et al.

Summary: Human liver stem cells (HLSCs) were first described in 2006 as a new stem cell population derived from healthy human livers, exhibiting multipotent and immunomodulatory properties. Research has shown that HLSCs can differentiate into various cell lineages under specific in vitro conditions, contributing to tissue repair and regeneration. Further studies are needed to elucidate the mechanisms of action of HLSCs and their potential therapeutic applications.

FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY (2021)

Article Obstetrics & Gynecology

Postoperative adjuvant dose-dense chemotherapy with bevacizumab and maintenance bevacizumab after neoadjuvant chemotherapy for advanced ovarian cancer: A phase II AGOG/TGOG trial

Hung-Hsueh Chou et al.

Summary: This study evaluated the safety and efficacy of adding bevacizumab to dose-dense adjuvant chemotherapy in ovarian, tubal, and primary peritoneal cancer patients. The results showed that this treatment regimen was feasible with tolerable toxicity and comparable progression-free survival and overall survival compared to other studies using bevacizumab.

EUROPEAN JOURNAL OF OBSTETRICS & GYNECOLOGY AND REPRODUCTIVE BIOLOGY (2021)

Article Oncology

Aflibercept or bevacizumab in combination with FOLFIRI as second-line treatment of mRAS metastatic colorectal cancer patients: the ARBITRATION study protocol

Alessandro Ottaiano et al.

Summary: The study aims to compare the efficacy of second-line treatments with FOLFIRI/bevacizumab beyond progression versus FOLFIRI/aflibercept in mRAS mCRC patients, and to identify angiogenic factors' patterns that could assist oncologists in applying anti-angiogenic strategies more effectively.

THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY (2021)

Article Oncology

Clinical Outcomes with Multikinase Inhibitors after Progression on First-Line Atezolizumab plus Bevacizumab in Patients with Advanced Hepatocellular Carcinoma: A Multinational Multicenter Retrospective Study

Changhoon Yoo et al.

Summary: In patients with advanced hepatocellular carcinoma who experienced disease progression on atezolizumab-bevacizumab, second-line treatment with multikinase inhibitors, predominantly sorafenib and lenvatinib, demonstrated comparable efficacy and manageable toxicities.

LIVER CANCER (2021)

Article Medicine, Research & Experimental

Estradiol modulated colorectal cancer stem cells bioactivity and interaction with endothelial cells

Arezoo Rezaie Nezhad Zamani et al.

LIFE SCIENCES (2020)

Article Biochemistry & Molecular Biology

The Adenosine A3 Receptor Regulates Differentiation of Glioblastoma Stem-Like Cells to Endothelial Cells under Hypoxia

Rene Rocha et al.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2018)

Editorial Material Immunology

IL-22 Gets to the Stem of Colorectal Cancer

Ekaterina K. Koltsova et al.

IMMUNITY (2014)